Abstract
To assess the efficacy and safety of LGX, an oral GnRH receptor antagonist, administered with and without hormonal add-back therapy (ABT: 1 mg estradiol/0.5 mg norethindrone acetate), for the treatment of HMB and other symptoms of UF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have